

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6329582

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CECILIA ANNA WILHELMINA GEUIJEN	08/24/2020
ROBERTUS CORNELIS ROOVERS	08/25/2020
MARK THROSBY	09/24/2020
CORNELIS ADRIAAN DE KRUIF	09/09/2020
TON LOGTENBERG	09/09/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MERUS N.V.
<b>Street Address:</b>	YALELAAN 62
<b>City:</b>	UTRECHT
<b>State/Country:</b>	NETHERLANDS
<b>Postal Code:</b>	3584 CM
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16637464
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2023712600
<b>Email:</b>	djackson@sternekessler.com, amoghal@sternekessler.com
<b>Correspondent Name:</b>	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
<b>Address Line 1:</b>	1100 NEW YORK AVE, NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005
<b>ATTORNEY DOCKET NUMBER:</b>	4096.0310001
<b>NAME OF SUBMITTER:</b>	PAUL A. CALVO
<b>SIGNATURE:</b>	/Paul A. Calvo, Reg. No. 57913/
<b>DATE SIGNED:</b>	10/01/2020
<b>Total Attachments: 11</b>	
source=Executed-Assignment-4096-0310001#page1.tif	

source=Executed-Assignment-4096-0310001#page2.tif  
source=Executed-Assignment-4096-0310001#page3.tif  
source=Executed-Assignment-4096-0310001#page4.tif  
source=Executed-Assignment-4096-0310001#page5.tif  
source=Executed-Assignment-4096-0310001#page6.tif  
source=Executed-Assignment-4096-0310001#page7.tif  
source=Executed-Assignment-4096-0310001#page8.tif  
source=Executed-Assignment-4096-0310001#page9.tif  
source=Executed-Assignment-4096-0310001#page10.tif  
source=Executed-Assignment-4096-0310001#page11.tif

### ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan DE KRUIF, and Ton LOGTENBERG**, hereby sell and assign to **Merus N.V.**, a corporation formed under the laws of The Netherlands, whose mailing address is Yalelaan 62, Utrecht, 3584 CM (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTIBODIES THAT BIND EGFR AND CMET** for which application(s) for patent in the United States of America has a filing date of February 7, 2020 (also known as United States Application No. 16/637,464, which is the U.S. national phase of International Application No. PCT/NL2018/050537, International Filing Date August 9, 2018), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.


The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 24 Aug 2010 Signature of Inventor:   
Cecilia Anna Wilhelmina  
GEUIJEN

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Robertus Cornelis ROOVERS

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Mark THROSBY

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cornelis Adriaan DE KRUIF

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Ton LOGTENBERG

### ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan DE KRUIF, and Ton LOGTENBERG**, hereby sell and assign to **Merus N.V.**, a corporation formed under the laws of The Netherlands, whose mailing address is Yalelaan 62, Utrecht, 3584 CM (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTIBODIES THAT BIND EGFR AND CMET** for which application(s) for patent in the United States of America has a filing date of February 7, 2020 (also known as United States Application No. 16/637,464, which is the U.S. national phase of International Application No. PCT/NL2018/050537, International Filing Date August 9, 2018), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.


The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cecilia Anna Wilhelmina  
GEUIJEN

Date: 25/08/2020 Signature of Inventor:   
Robertus Cornelis ROOVERS

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Mark THROSBY

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cornelis Adriaan DE KRUIF

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Ton LOGTENBERG

### ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan DE KRUIF, and Ton LOGTENBERG**, hereby sell and assign to **Merus N.V.**, a corporation formed under the laws of The Netherlands, whose mailing address is Yalelaan 62, Utrecht, 3584 CM (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTIBODIES THAT BIND EGFR AND CMET** for which application(s) for patent in the United States of America has a filing date of February 7, 2020 (also known as United States Application No. 16/637,464, which is the U.S. national phase of International Application No. PCT/NL2018/050537, International Filing Date August 9, 2018), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cecilia Anna Wilhelmina  
GEUIJEN

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Robertus Cornelis ROOVERS

Date: 24/09/2020 Signature of Inventor: [Signature]  
Mark THROSBY

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cornelis Adriaan DE KRUIF

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Ton LOGTENBERG



### ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan DE KRUIF, and Ton LOGTENBERG**, hereby sell and assign to **Merus N.V.**, a corporation formed under the laws of The Netherlands, whose mailing address is Yalelaan 62, Utrecht, 3584 CM (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTIBODIES THAT BIND EGFR AND CMET** for which application(s) for patent in the United States of America has a filing date of February 7, 2020 (also known as United States Application No. 16/637,464, which is the U.S. national phase of International Application No. PCT/NL2018/050537, International Filing Date August 9, 2018), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cecilia Anna Wilhelmina  
GEUIJEN

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Robertus Cornelis ROOVERS

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Mark THROSBY

Date: 07 Sep 20 Signature of Inventor: \_\_\_\_\_  
Cornelis Adriaan DE KRUIF

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Ton LOGTENBERG

### ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan DE KRUIF, and Ton LOGTENBERG**, hereby sell and assign to **Merus N.V.**, a corporation formed under the laws of The Netherlands, whose mailing address is Yalelaan 62, Utrecht, 3584 CM (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTIBODIES THAT BIND EGFR AND CMET** for which application(s) for patent in the United States of America has a filing date of February 7, 2020 (also known as United States Application No. 16/637,464, which is the U.S. national phase of International Application No. PCT/NL2018/050537, International Filing Date August 9, 2018), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.


IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cecilia Anna Wilhelmina  
GEUIJEN

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Robertus Cornelis ROOVERS

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Mark THROSBY

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Cornelis Adriaan DE KRUIF

Date: 9 Sept 2020 Signature of Inventor:   
Ton LOGTENBERG

SIGNED on behalf of the said ASSIGNEE,

MERUS NV.

By: 

Name: Eyal Goren

Title: CEO, General Counsel, Head of IP

Date: Aug. 31, 2020

14777933.1